Key result
hERG1 activator NS1643 irreversibly inhibits breast cancer proliferation via senescence, increasing G0/G1 fraction by ~82%.
Why the study?
The role of the hERG1 potassium channel in cancer biology, particularly in breast cancer cells, is unknown and controversial regarding its effect on cell death and proliferation.
Absolute Event Rate: 69% vs 38%
p-value: p=<0.005
Prolonged stimulation of the hERG1 potassium channel by NS1643 activates a senescence program in breast cancer cells, suggesting a potential antiproliferative cancer therapy.
May support hERG1 activation for senescence induction in breast cancer; leaves open in vivo efficacy and clinical translation.
Traditionally the hERG1 potassium channel has been known to have a fundamental role in membrane excitability of several mammalian cells including cardiac myocytes. hERG1 has recently been found to be expressed in non-excitable cancer cells of different histogenesis, but the role of this channel in cancer biology is unknown. Results form recent studies on the effect hERG1 inhibition in some breast cancer cells are controversial as it can lead to apoptosis or protect against cell death. Nevertheless, these data suggest that the hERG1 channel could have an important role in cancer biology. Here we report the effects of hyperstimulation of hERG1 channel in human mammary gland adenocarcinoma-derived cells. Application of the hERG1 activator, the diphenylurea derivative NS1643, inhibits cell proliferation irreversibly. This event is accompanied by a preferential arrest of the cell cycle in G0/G1 phase without the occurrence of apoptotic events. Consequently, cells responded to NS1643 by developing a senescence-like phenotype associated with increased protein levels of the tumor suppressors p21 and p16(INK4a) and by a positive β-galactosidase assay. These data suggest that prolonged stimulation of the hERG1 potassium channel may activate a senescence program and offers a compelling opportunity to develop a potential antiproliferative cancer therapy.
No takes yet. Share an insight, caveat, or question.
Lansu et al. (2013) studied Breast cancer (in vitro). NS1643 vs. Untreated cells / DMSO was evaluated on Cell fraction in G0/G1 phase at 48 hours (SKBr3 cells) (p=<0.005). The hERG1 activator NS1643 irreversibly inhibited breast cancer cell proliferation, increasing the G0/G1 cell fraction from 38% to 69% and activating a senescence program.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: